The 54^th Annual Meeting of the American Society of Haematology (ASH) took place on the 8 – 12 December inAtlanta,USA. This year, some 200 talks and over 500 posters dedicated to myeloma research were presented. Here, we summarise some of the highlights emerging from the conference: Continue reading →

The latest results from an international Phase III clinical study, show that pomalidomide with low-dose dexamethasone improves the length of remission and extends overall survival in relapsed and refractory myeloma patients.

Pomalidomide, an immunomodulatory drug (IMiD) similar to Revlimid® and derived from thalidomide, is being developed by the pharmaceutical company Celgene as a potential treatment in myeloma. Continue reading →

MPE has welcomed the news today that the European Commission has approved a marketing licence for Velcade to be used as a subcutaneous (under the skin) injection for myeloma patients.

Velcade was the first in a class of anti-cancer drugs called proteasome inhibitors to be used in myeloma. It was first licensed in Europe in an IV formulation and since then Velcade has had a significant impact on the treatment of myeloma. Continue reading →